Incyte's Fourth-Quarter Report Signals Better Times Ahead
On Thursday, Incyte (NASDAQ: INCY) reported results from 2019's fourth quarter that suggest 2020 could be a great year for the company, despite disappointing clinical trial results announced in January.
Revenue surged 24% year over year to $579 million, which was slightly above the consensus estimate. On the bottom line, Incyte reported adjusted earnings of $0.65 per share for the quarter, which exceeded analysts' average expectation by 12%.
Source Fool.com
